大麻二酚起始和滴定后需调整华法林剂量
本文报告一例46岁男性深静脉血栓患者,在开始使用FDA批准的大麻二酚产品(Epidiolex)并滴定剂量期间,密切监测INR,需将华法林剂量降低近20%以维持INR在目标范围。另有一例已发表病例报告显示,类似情况下患者INR升至6.86,需将华法林周剂量降低30%才重新达到目标INR。结论支持大麻二酚与华法林存在相互作用,建议频繁监测INR。
要点
- 开始大麻二酚治疗时,华法林剂量需降低近20%以维持INR达标。
- 另一病例中INR升至6.86,华法林周剂量需降低30%才恢复目标INR。
- 使用华法林患者启用FDA批准大麻二酚时应频繁监测INR。
核心结论
- 本病例报告支持先前发表的大麻二酚与华法林存在相互作用的报告。
- 华法林患者开始使用FDA批准的大麻二酚时应频繁监测INR。
- 需要进一步研究以明确大麻二酚与华法林的相互作用潜力。
研究设计与样本
- 个案报告:一例46岁男性深静脉血栓患者,服用华法林期间起始FDA批准的大麻二酚产品(Epidiolex)用于难治性癫痫。
- 在大麻二酚起始和剂量滴定期间密切监测INR。
主要发现
- 患者开始大麻二酚后需将华法林剂量降低近20%以维持INR在目标范围。
- 另一已发表病例报告中,患者INR升至6.86,需将华法林周剂量降低30%才重新达到目标INR。
关键数值与推荐
- 本病例:华法林剂量降低近20%以维持INR在目标范围。
- 另一病例:INR达6.86,华法林周剂量降低30%以重新达到目标INR。
临床怎么用
- 服用华法林的患者开始FDA批准的大麻二酚治疗时,应频繁监测INR。
- 根据INR监测结果,可能需要降低华法林剂量(本病例降低近20%)。
局限性
- 本文为个案报告,证据级别有限。
- 需要额外研究来阐明大麻二酚与华法林的相互作用潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A case of a possible interaction between cannabidiol and warfarin is presented along with a brief overview of cytochrome enzymes involved in these drugs' metabolism. SUMMARY: A 46-year-old male taking warfarin for treatment of a deep venous thrombosis was initiated on a Food and Drug Administration (FDA)-approved cannabidiol product (Epidiolex, Greenwich Biosciences) for intractable epilepsy. The patient's International Normalized Ratio (INR) was monitored closely during cannabidiol initiation and dose titration. The patient required a nearly 20% warfarin dose reduction to maintain an INR within the goal range after starting therapy with cannabidiol. There is 1 other case report describing a clinically significant interaction between cannabidiol (specifically Epidiolex) and warfarin in a patient receiving warfarin who was enrolled in a study involving the initiation and titration of cannabidiol; that patient developed a supratherapeutic INR of 6.86 and required a 30% reduction in the weekly warfarin dose to reachieve the goal INR. CONCLUSION: A previously published report suggesting an interaction between cannabidiol and warfarin is supported by this case report. INR should be monitored frequently in patients taking warfarin who begin to take FDA-approved cannabidiol. Additional studies should be performed to clarify the interaction potential of cannabidiol and warfarin.
引用
- Cortopassi J. Warfarin dose adjustment required after cannabidiol initiation and titration. Am J Health Syst Pharm. 2020. PMID: 33016308. doi:10.1093/ajhp/zxaa268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。